A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 555,642 shares of NVO stock, worth $60 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
555,642
Previous 599,711 7.35%
Holding current value
$60 Million
Previous $85.6 Million 22.71%
% of portfolio
0.09%
Previous 0.12%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$119.07 - $145.42 $5.25 Million - $6.41 Million
-44,069 Reduced 7.35%
555,642 $66.2 Million
Q2 2024

Jul 19, 2024

BUY
$122.71 - $146.91 $7.16 Million - $8.57 Million
58,357 Added 10.78%
599,711 $85.6 Million
Q1 2024

Apr 22, 2024

BUY
$102.11 - $135.92 $5.29 Million - $7.05 Million
51,844 Added 10.59%
541,354 $69.5 Million
Q4 2023

Jan 16, 2024

BUY
$87.78 - $105.45 $11.4 Million - $13.7 Million
129,739 Added 36.06%
489,510 $50.6 Million
Q3 2023

Oct 24, 2023

BUY
$90.94 - $199.54 $19.4 Million - $42.6 Million
213,360 Added 145.73%
359,771 $32.7 Million
Q2 2023

Jul 25, 2023

SELL
$155.98 - $172.65 $1.58 Million - $1.75 Million
-10,117 Reduced 6.46%
146,411 $23.7 Million
Q1 2023

Apr 14, 2023

BUY
$132.34 - $159.14 $4.82 Million - $5.8 Million
36,438 Added 30.34%
156,528 $24.9 Million
Q4 2022

Feb 08, 2023

BUY
$102.55 - $135.33 $968,277 - $1.28 Million
9,442 Added 8.53%
120,090 $16.3 Million
Q3 2022

Oct 25, 2022

SELL
$95.28 - $116.93 $1.21 Million - $1.49 Million
-12,718 Reduced 10.31%
110,648 $11 Million
Q2 2022

Aug 12, 2022

SELL
$103.24 - $121.81 $4.58 Million - $5.4 Million
-44,329 Reduced 26.43%
123,366 $13.7 Million
Q1 2022

May 11, 2022

BUY
$93.1 - $112.54 $399,399 - $482,796
4,290 Added 2.63%
167,695 $18.6 Million
Q4 2021

Feb 08, 2022

BUY
$95.88 - $117.08 $7,862 - $9,600
82 Added 0.05%
163,405 $18.3 Million
Q3 2021

Nov 02, 2021

BUY
$84.42 - $106.62 $321,977 - $406,648
3,814 Added 2.39%
163,323 $15.7 Million
Q2 2021

Aug 11, 2021

BUY
$67.66 - $84.76 $173,615 - $217,494
2,566 Added 1.63%
159,509 $13.4 Million
Q1 2021

May 14, 2021

BUY
$67.06 - $75.82 $3.14 Million - $3.55 Million
46,790 Added 42.48%
156,943 $10.6 Million
Q4 2020

Feb 12, 2021

SELL
$63.89 - $73.8 $5.28 Million - $6.1 Million
-82,659 Reduced 42.87%
110,153 $7.69 Million
Q3 2020

Nov 04, 2020

BUY
$63.69 - $70.22 $3.7 Million - $4.08 Million
58,157 Added 43.19%
192,812 $13.4 Million
Q2 2020

Jul 17, 2020

BUY
$58.54 - $67.94 $2.26 Million - $2.62 Million
38,607 Added 40.2%
134,655 $8.82 Million
Q1 2020

Apr 21, 2020

BUY
$49.46 - $64.78 $178,451 - $233,726
3,608 Added 3.9%
96,048 $5.78 Million
Q4 2019

Feb 12, 2020

BUY
$49.86 - $58.26 $175,208 - $204,725
3,514 Added 3.95%
92,440 $5.35 Million
Q3 2019

Nov 07, 2019

SELL
$47.54 - $53.43 $1.53 Million - $1.72 Million
-32,208 Reduced 26.59%
88,926 $4.6 Million
Q2 2019

Aug 06, 2019

SELL
$46.79 - $52.47 $361,031 - $404,858
-7,716 Reduced 5.99%
121,134 $6.18 Million
Q1 2019

May 06, 2019

BUY
$46.36 - $52.63 $28,650 - $32,525
618 Added 0.48%
128,850 $6.74 Million
Q4 2018

Feb 11, 2019

SELL
$41.54 - $47.25 $782,904 - $890,520
-18,847 Reduced 12.81%
128,232 $5.91 Million
Q3 2018

Nov 14, 2018

BUY
$46.76 - $51.24 $75,938 - $83,213
1,624 Added 1.12%
147,079 $6.93 Million
Q2 2018

Jul 30, 2018

BUY
$44.29 - $50.42 $1.9 Million - $2.16 Million
42,938 Added 41.88%
145,455 $6.71 Million
Q1 2018

Apr 16, 2018

BUY
$48.49 - $58.14 $527,959 - $633,028
10,888 Added 11.88%
102,517 $5.05 Million
Q4 2017

Feb 09, 2018

BUY
$47.53 - $53.73 $428,625 - $484,537
9,018 Added 10.92%
91,629 $4.92 Million
Q3 2017

Oct 26, 2017

SELL
$41.15 - $49.22 $385,781 - $461,437
-9,375 Reduced 10.19%
82,611 $3.98 Million
Q2 2017

Aug 15, 2017

BUY
N/A
91,986
91,986 $3.95 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $244B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.